Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has received an average rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $75.71.
A number of equities analysts have recently commented on IONS shares. UBS Group started coverage on Ionis Pharmaceuticals in a report on Thursday, October 15th. They issued a “buy” rating and a $88.00 price objective on the stock. Wells Fargo & Company decreased their price objective on shares of Ionis Pharmaceuticals from $95.00 to $80.00 and set an “overweight” rating for the company in a research note on Tuesday, November 10th. TD Cowen dropped their price objective on shares of Ionis Pharmaceuticals from $84.00 to $53.00 and set a “buy” rating for the company in a research report on Tuesday, November 10th. Weiss Ratings downgraded shares of Ionis Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Finally, JPMorgan Chase & Co. reduced their target price on shares of Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, September 22nd.
Read Our Latest Analysis on Ionis Pharmaceuticals
Ionis Pharmaceuticals Price Performance
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.57. The firm had revenue of $242.72 million for the quarter, compared to analyst estimates of $178.17 million. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. Ionis Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.80) earnings per share. On average, analysts forecast that Ionis Pharmaceuticals will post -3.57 EPS for the current fiscal year.
Insider Activity
In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of the business’s stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the transaction, the executive vice president owned 17,811 shares in the company, valued at $775,490.94. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Hayden acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were purchased at an average price of $29.64 per share, for a total transaction of $148,200.00. Following the purchase, the director directly owned 27,000 shares of the company’s stock, valued at approximately $800,280. This trade represents a 22.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.81% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of IONS. Virtu Financial LLC bought a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at about $483,000. Allworth Financial LP lifted its holdings in Ionis Pharmaceuticals by 537.6% in the third quarter. Allworth Financial LP now owns 3,290 shares of the company’s stock worth $147,000 after acquiring an additional 2,774 shares during the last quarter. Quantitative Investment Management LLC acquired a new position in Ionis Pharmaceuticals in the third quarter valued at approximately $423,000. Quarry LP boosted its stake in Ionis Pharmaceuticals by 6,796.6% in the third quarter. Quarry LP now owns 2,000 shares of the company’s stock valued at $89,000 after acquiring an additional 1,971 shares during the period. Finally, Aquatic Capital Management LLC grew its holdings in shares of Ionis Pharmaceuticals by 39.9% during the third quarter. Aquatic Capital Management LLC now owns 59,561 shares of the company’s stock valued at $2,659,000 after purchasing an additional 16,980 shares during the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Featured Stories
- Five stocks we like better than Ionis Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
